Gilead Sciences Buy Hold or Sell Recommendation

GILD -- USA Stock  

USD 75.51  0.52  0.69%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Gilead Sciences is 'Strong Hold'. Macroaxis provides Gilead Sciences buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GILD positions. The advice algorithm takes into account all of Gilead Sciences available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from GILD buy-and-hold prospective. Please also check Gilead Sciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Gilead SciencesBuy Gilead Sciences
Strong Hold

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon Gilead Sciences has a risk adjusted performance of 0.0401, jensen alpha of 0.0579, total risk alpha of 0.07, sortino ratio of 0.0214 and treynor ratio of 0.1842
Macroaxis provides unbiased buy or sell recommendations on Gilead Sciences that should be used to complement current analysts and expert consensus on Gilead Sciences. Our buy, hold, or sell suggestion engine determines the entity potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Gilead Sciences is not overpriced, please check out all Gilead Sciences fundamentals including its Gross Profit, Debt to Equity and the relationship between Price to Book and Cash and Equivalents . Given that Gilead Sciences has Price to Earning of 45.11 times, we strongly advise you confirm Gilead Sciences market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Gilead Sciences Thematic Classifications

Macroaxis Index IdeaMacroaxis Index
Macroaxis power theme of selected equities with solid fundamentals
Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Gilead Sciences Returns Distribution Density

Mean Return0.09Value At Risk1.9
Potential Upside2.36Standard Deviation1.22
 Return Density 
      Distribution 

Institutional Investors

Security TypeSharesValue
Blackrock IncCommon Shares105.2 M7.5 B
Vanguard Group IncCommon Shares96.1 M6.8 B
Capital Research Global InvestorsCommon Shares57 M4 B
State Street CorpCommon Shares54.4 M3.9 B
Bank Of New York Mellon CorpCommon Shares31 M2.2 B
Fmr LlcCommon Shares19.6 M1.4 B
Parnassus InvestmentsCommon Shares19.5 M1.4 B

Gilead Sciences Greeks

α
Alpha over DOW
=0.06
β
Beta against DOW=0.45
σ
Overall volatility
=1.20
Ir
Information ratio =0.0223

Gilead Sciences Volatility Alert

Gilead Sciences has relatively low volatility with skewness of 0.17 and kurtosis of -0.27. However, we advise all investors to independently investigate Gilead Sciences to ensure market all accessible information is consistent with the expectations about its upside potential and future risk-adjusted return.
    
 Better Than Average     
    
 Worse Than Average Compare Gilead Sciences to competition

Gilead Sciences Fundamental Vs Peers

FundamentalsGilead SciencesPeer Average
Return On Equity9.97 % (15.17) %
Return On Asset10.77 % (15.64) %
Profit Margin9.52 % (5.50) %
Operating Margin52.72 % (10.91) %
Current Valuation97.14 B152.14 B
Shares Outstanding1.3 B1.43 B
Shares Owned by Insiders0.67 % 6.91 %
Shares Owned by Institutions81.11 % 18.37 %
Number of Shares Shorted13.52 M3.24 M
Price to Earning45.11 times40.69 times
Price to Book4.52 times14.44 times
Price to Sales4.22 times17.81 times
Revenue23.2 B9.85 B
Gross Profit21.75 B21.75 B
EBITDA12.23 B1.41 B
Net Income2.21 B517.71 M
Cash and Equivalents27.1 B3.89 B
Cash per Share20.91 times5.17 times
Total Debt29.06 B7.36 B
Debt to Equity133.70 % 0.72 %
Current Ratio3.00 times3.30 times
Book Value Per Share16.72 times13.64 times
Cash Flow from Operations8.31 B1.25 B
Short Ratio2.22 times2.09 times
Earnings Per Share1.67 times2.30 times
Price to Earnings To Growth2.05 times1.22 times
Number of Employees10 K10.67 K
Beta1.420.34
Market Capitalization97.89 B29.78 B
Total Asset1.29 B126.86 B
Retained Earnings18.15 B38.24 B
Working Capital1.08 B3.58 B
Current Asset1.18 B36.8 B
   Sale by William Lee of 1985 shares of Gilead Sciences [view details]

Gilead Sciences Alerts

Trading Alerts and Improvement Suggestions

Gilead Sciences has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
Over 81.0% of the company shares are owned by institutional investors
On September 13, 2018 Gilead Sciences paid $ 0.57 per share dividend to its current shareholders
Latest headline from stocknewsgazette.com: Nutrien Ltd. is better stock pick than Gilead Sciences, Inc.

Latest Analysts View

Gilead Sciences Current Analysts Recommendations

Target Median Price88.50
Target Mean Price88.00
Recommendation Mean2.10
Target High Price106.00
Number Of Analyst Opinions22
Target Low Price71.00
Please also check Gilead Sciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Search macroaxis.com